PHAR (Pharming Group) Ending Cash Position: $158.3 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PHAR Pharming Group PHAR
78 GF Score
Price $10.26
GF Value $12.90
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Pharming Group Ending Cash Position?

Pharming Group PHAR +4.48% 78 Ending Cash Position is $158.3 Mil as of Jun. 2026. GuruFocus rates PHAR with a GF Score™ of 78/100 and a GF Value™ of $12.90 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Pharming Group's Ending Cash Position for the quarter that ended in Jun. 2026 was $158.3 Mil.

Pharming Group's quarterly Ending Cash Position declined from Dec. 2025 ($145.3 Mil) to Mar. 2026 ($52.4 Mil) but then increased from Mar. 2026 ($52.4 Mil) to Jun. 2026 ($158.3 Mil).

Pharming Group's annual Ending Cash Position declined from Dec. 2023 ($61.7 Mil) to Dec. 2024 ($54.9 Mil) but then increased from Dec. 2024 ($54.9 Mil) to Dec. 2025 ($145.3 Mil).

Pharming Group Ending Cash Position Related Terms

Pharming Group Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Pharming Group's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharming Group Ending Cash Position Chart

Pharming Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 191.92 207.34 61.74 54.94 145.31

Pharming Group Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 92.09 132.37 145.31 52.38 158.28
PHAR
78GF Score
Pharming Group PHAR
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharming Group Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Pharming Group's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=54.943+90.362
=145.3

Pharming Group's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=170.176+-11.895
=158.3

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $158.3 Mil mean?
Pharming Group (PHAR) has a Ending Cash Position of $158.3 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Pharming Group and its competitors.
Is Pharming Group's Ending Cash Position too high?
Pharming Group's current Ending Cash Position is $158.3 Mil. Overall, Pharming Group has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharming Group's Ending Cash Position compare to VRTX and REGN?
Pharming Group's Ending Cash Position of $158.3 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Pharming Group and its competitors. Pharming Group's current Ending Cash Position is $158.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharming Group stock overvalued right now?
Based on GuruFocus' analysis, Pharming Group (PHAR) is currently considered Modestly Undervalued. The stock's GF Value™ is $12.90, compared to a current price of $10.26 — trading 20.5% below its estimated fair value. The current Ending Cash Position is $158.3 Mil. Pharming Group's overall GF Score™ is 78/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Pharming Group (PHAR), the current Ending Cash Position is $158.3 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharming Group (PHAR) Overvalued in 2026?

Based on GuruFocus' analysis, Pharming Group stock appears to be undervalued. The current stock price of $10.26 is trading 20.5% below its estimated GF Value™ of $12.90. GuruFocus considers Pharming Group to be Modestly Undervalued.

Key valuation signals for PHAR:

  • Ending Cash Position: $158.3 Mil
  • GF Value™: $12.90 vs. price of $10.26 (20.5% below fair value)
  • GF Score™: 78/100 with 2 warning signs

No single metric tells the full story. See the PHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharming Group Business Description

Address Darwinweg 24, Leiden, ZH, NLD, 2333 CR
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
78GF Score

Get the complete analysis for PHAR

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.26
Price
$12.90
GF Value